Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs

Bom Jung, Man Kyu Shim, Min Ju Park, Eun Hyang Jang, Hong Yeol Yoon, Kwang Meyung Kim, Jong Ho Kim

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

This study presented the development of hydrophobically modified polysialic acid (HPSA) nanoparticles, a novel anticancer drug nanocarrier that increases therapeutic efficacy without causing nonspecific toxicity towards normal cells. HPSA nanoparticles were prepared by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC)/N-hydroxysuccinimide (NHS) coupling between N-deacetylated polysialic acid (PSA) and 5β-cholanic acid. The physicochemical characteristics of HPSA nanoparticles (zeta-potential, morphology and size) were measured, and in vitro cytotoxicity and cellular uptake of PSA and HPSA nanoparticles were tested in A549 cells. In vivo cancer targeting of HPSA nanoparticles was evaluated by labeling PSA and HPSA nanoparticles with Cy5.5, a near-infrared fluorescent dye, for imaging. HPSA nanoparticles showed improved cancer-targeting ability compared with PSA. Doxorubicin-loaded HPSA (DOX-HPSA) nanoparticles were prepared using a simple dialysis method. An analysis of the in vitro drug-release profile and drug-delivery behavior showed that DOX was effectively released from DOX-HPSA nanoparticles. In vivo cancer therapy with DOX-HPSA nanoparticles in mice showed antitumor effects that resembled those of free DOX. Moreover, DOX-HPSA nanoparticles had low toxicity toward other organs, reflecting their tumor-targeting property. Hence, HPSA nanoparticles are considered a potential nanocarrier for anticancer agents.

Original languageEnglish
Pages (from-to)111-118
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume520
Issue number1-2
DOIs
Publication statusPublished - 2017 Mar 30
Externally publishedYes

Fingerprint

Drug Carriers
Nanoparticles
Polysaccharides
Doxorubicin
polysialic acid
Neoplasms
Ethyldimethylaminopropyl Carbodiimide
Aptitude
Fluorescent Dyes
Pharmaceutical Preparations
Antineoplastic Agents
Dialysis

Keywords

  • Doxorubicin
  • EPR effect
  • Nanoparticles
  • Polysialic acid
  • Targeted cancer therapy

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs. / Jung, Bom; Shim, Man Kyu; Park, Min Ju; Jang, Eun Hyang; Yoon, Hong Yeol; Kim, Kwang Meyung; Kim, Jong Ho.

In: International Journal of Pharmaceutics, Vol. 520, No. 1-2, 30.03.2017, p. 111-118.

Research output: Contribution to journalArticle

Jung, Bom ; Shim, Man Kyu ; Park, Min Ju ; Jang, Eun Hyang ; Yoon, Hong Yeol ; Kim, Kwang Meyung ; Kim, Jong Ho. / Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs. In: International Journal of Pharmaceutics. 2017 ; Vol. 520, No. 1-2. pp. 111-118.
@article{01f0e8820b994ba289505abc51c84aae,
title = "Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs",
abstract = "This study presented the development of hydrophobically modified polysialic acid (HPSA) nanoparticles, a novel anticancer drug nanocarrier that increases therapeutic efficacy without causing nonspecific toxicity towards normal cells. HPSA nanoparticles were prepared by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC)/N-hydroxysuccinimide (NHS) coupling between N-deacetylated polysialic acid (PSA) and 5β-cholanic acid. The physicochemical characteristics of HPSA nanoparticles (zeta-potential, morphology and size) were measured, and in vitro cytotoxicity and cellular uptake of PSA and HPSA nanoparticles were tested in A549 cells. In vivo cancer targeting of HPSA nanoparticles was evaluated by labeling PSA and HPSA nanoparticles with Cy5.5, a near-infrared fluorescent dye, for imaging. HPSA nanoparticles showed improved cancer-targeting ability compared with PSA. Doxorubicin-loaded HPSA (DOX-HPSA) nanoparticles were prepared using a simple dialysis method. An analysis of the in vitro drug-release profile and drug-delivery behavior showed that DOX was effectively released from DOX-HPSA nanoparticles. In vivo cancer therapy with DOX-HPSA nanoparticles in mice showed antitumor effects that resembled those of free DOX. Moreover, DOX-HPSA nanoparticles had low toxicity toward other organs, reflecting their tumor-targeting property. Hence, HPSA nanoparticles are considered a potential nanocarrier for anticancer agents.",
keywords = "Doxorubicin, EPR effect, Nanoparticles, Polysialic acid, Targeted cancer therapy",
author = "Bom Jung and Shim, {Man Kyu} and Park, {Min Ju} and Jang, {Eun Hyang} and Yoon, {Hong Yeol} and Kim, {Kwang Meyung} and Kim, {Jong Ho}",
year = "2017",
month = "3",
day = "30",
doi = "10.1016/j.ijpharm.2017.01.055",
language = "English",
volume = "520",
pages = "111--118",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs

AU - Jung, Bom

AU - Shim, Man Kyu

AU - Park, Min Ju

AU - Jang, Eun Hyang

AU - Yoon, Hong Yeol

AU - Kim, Kwang Meyung

AU - Kim, Jong Ho

PY - 2017/3/30

Y1 - 2017/3/30

N2 - This study presented the development of hydrophobically modified polysialic acid (HPSA) nanoparticles, a novel anticancer drug nanocarrier that increases therapeutic efficacy without causing nonspecific toxicity towards normal cells. HPSA nanoparticles were prepared by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC)/N-hydroxysuccinimide (NHS) coupling between N-deacetylated polysialic acid (PSA) and 5β-cholanic acid. The physicochemical characteristics of HPSA nanoparticles (zeta-potential, morphology and size) were measured, and in vitro cytotoxicity and cellular uptake of PSA and HPSA nanoparticles were tested in A549 cells. In vivo cancer targeting of HPSA nanoparticles was evaluated by labeling PSA and HPSA nanoparticles with Cy5.5, a near-infrared fluorescent dye, for imaging. HPSA nanoparticles showed improved cancer-targeting ability compared with PSA. Doxorubicin-loaded HPSA (DOX-HPSA) nanoparticles were prepared using a simple dialysis method. An analysis of the in vitro drug-release profile and drug-delivery behavior showed that DOX was effectively released from DOX-HPSA nanoparticles. In vivo cancer therapy with DOX-HPSA nanoparticles in mice showed antitumor effects that resembled those of free DOX. Moreover, DOX-HPSA nanoparticles had low toxicity toward other organs, reflecting their tumor-targeting property. Hence, HPSA nanoparticles are considered a potential nanocarrier for anticancer agents.

AB - This study presented the development of hydrophobically modified polysialic acid (HPSA) nanoparticles, a novel anticancer drug nanocarrier that increases therapeutic efficacy without causing nonspecific toxicity towards normal cells. HPSA nanoparticles were prepared by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC)/N-hydroxysuccinimide (NHS) coupling between N-deacetylated polysialic acid (PSA) and 5β-cholanic acid. The physicochemical characteristics of HPSA nanoparticles (zeta-potential, morphology and size) were measured, and in vitro cytotoxicity and cellular uptake of PSA and HPSA nanoparticles were tested in A549 cells. In vivo cancer targeting of HPSA nanoparticles was evaluated by labeling PSA and HPSA nanoparticles with Cy5.5, a near-infrared fluorescent dye, for imaging. HPSA nanoparticles showed improved cancer-targeting ability compared with PSA. Doxorubicin-loaded HPSA (DOX-HPSA) nanoparticles were prepared using a simple dialysis method. An analysis of the in vitro drug-release profile and drug-delivery behavior showed that DOX was effectively released from DOX-HPSA nanoparticles. In vivo cancer therapy with DOX-HPSA nanoparticles in mice showed antitumor effects that resembled those of free DOX. Moreover, DOX-HPSA nanoparticles had low toxicity toward other organs, reflecting their tumor-targeting property. Hence, HPSA nanoparticles are considered a potential nanocarrier for anticancer agents.

KW - Doxorubicin

KW - EPR effect

KW - Nanoparticles

KW - Polysialic acid

KW - Targeted cancer therapy

UR - http://www.scopus.com/inward/record.url?scp=85011900736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011900736&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2017.01.055

DO - 10.1016/j.ijpharm.2017.01.055

M3 - Article

C2 - 28179099

AN - SCOPUS:85011900736

VL - 520

SP - 111

EP - 118

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -